Short answer
Pediatrix Medical Group, Inc. (MD) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 results covered the three months ended March 31, 2026.
Pediatrix Medical Group, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results covered the three months ended March 31, 2026
- Press release issued May 5, 2026, with financial details in Exhibit 99.1
- Results disclosure enables investors to assess quarterly operating performance and financial condition
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenue $476.2M, up from $458.4M, with same-unit growth of 2.8% despite patient volume declining 1.6%
- Adjusted EBITDA $58.2M versus $49.2M, supporting reaffirmed 2026 guidance of $280M-$300M
- Net income $29.6M and EPS $0.36 versus $20.7M and $0.24; Adjusted EPS rose to $0.44 from $0.33
- Cash fell to $205.8M after $129.5M operating use, $21.5M repurchases, $7.0M acquisitions and $6.2M capital expenditures
- Debt $591M, including $400M 5.375% notes due 2030 and $191M Term A Loan; $450M revolver undrawn
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Pediatrix Medical Group, Inc. 8-K filings
Get the next MD 8-K as it lands
Follow MD for push alerts, or ask the research agent what this filing means.